U.S. Cancer Treatment Market – Industry Trends and Forecast to 2029

Market Analysis and Insights: U.S. Cancer Treatment Market

The U.S. cancer treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.8% in the forecast period of 2022 to 2029 and is expected to reach USD 223,234.64 million by 2029 from USD 86,942.10 million in 2021. The high prevalence of cancer and increasing R&D activities for its effective application are likely to be the major drivers that propel the market's demand in the forecast period.

Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor. This process is called metastases. The cancerous tumor is also referred to as a malignant tumor. The benign tumor does not invade nearby tissues, and when removed, benign tumors usually don't grow back, whereas cancerous tumors sometimes do.

There are more than a hundred types of cancer. Some categories of cancers that begin in specific types of cells include carcinoma, sarcoma, leukemia, lymphoma, and multiple myeloma, among others. Based on the type of cancer, many types of cancer treatments are available. Cancer treatment includes biomarker testing for cancer treatment, chemotherapy, hormone therapy, hyperthermia, immunotherapy, photodynamic therapy, radiation therapy, surgery, stem cell transplant, and targeted therapies.

According to GLOBOCAN, 19,292,789 new cancer cases were found in 2020 worldwide. The highest cases of breast cancer were found. Therefore, the high prevalence of cancer, initiatives taken by the government for awareness and early detection of cancer, and ongoing clinical trials are expected to fuel the market's growth. The cancer burden in the region and the rise in awareness initiatives taken by various organizations are expected to act as a driver for the growth of the market. However, the high cost of cancer treatment may restrain the market growth. The presence of big market players in the region is expected to act as an opportunity for the market's growth. However, the side effects of drugs may challenge the market's growth.

The U.S. cancer treatment market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

U.S. Cancer Treatment Market Scope and Market Size

The U.S. cancer treatment market is categorized into four notable segments based on cancer type, treatment, route of administration, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of cancer type, the U.S. cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma. In 2022, the breast cancer segment is expected to dominate the market because of the high prevalence of breast cancer.
• On the basis of treatment, the U.S. cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others. In 2022, the medication segment is expected to dominate the market because of increasing FDA approvals of cancer drugs in the region.
• On the basis of route of administration, the U.S. cancer treatment market is segmented into injectable, oral, and others. In 2022, the injectable segment is expected to dominate the market because of the easy availability of cancer treatment in injectable form.
• On the basis of end user, the U.S. cancer treatment market is segmented into hospitals and specialty clinics. In 2022, the hospitals segment is expected to dominate the market due to the presence of large hospitals in the country offering advanced cancer treatment.

U.S. Cancer Treatment Market Country Level Analysis

The U.S. cancer treatment market is analyzed, and market size information is provided by country, cancer type, treatment, route of administration, and end user.

The U.S. is expected to grow due to big market players present in the region. The players are launching advanced cancer treatment medications for the patients.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of U.S. brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the U.S. Cancer Treatment Market

The U.S. cancer treatment market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the dental instruments market. The data is available for the historical period 2011 to 2020.

Competitive Landscape and U.S. Cancer Treatment Market Share Analysis

The U.S. cancer treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the U.S. cancer treatment market.

Some of the major companies in the U.S. cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for cancer treatment are bridging the gap for various treatments.

For instance,

• In October 2021, Novartis AG announced that it had received FDA approval for its Scemblix (asciminib) to treat chronic myeloid leukemia (CML). This will help the company to increase its revenue

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the cancer treatment market, which also benefits the organization to improve their offering for the U.S. cancer treatment market.

 

---

SKU-67334